BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ChemDiv, Inc. Enters Into Research and Collaboration Agreement With Janssen Pharmaceutica N.V. and Tibotec Pharmaceuticals Ltd


12/20/2011 8:47:00 AM

SAN DIEGO, CA and MOSCOW--(Marketwire - December 20, 2011) - ChemDiv, Inc. (ChemDiv) announced today that it has entered into a multi-project research and collaboration agreement with Janssen Pharmaceutica NV (Janssen) and Tibotec Pharmaceuticals (Tibotec). Under the arrangement, ChemDiv will apply its integrated drug discovery expertise and technologies to identify novel small molecules against targets to be jointly agreed upon. For each research project, Janssen or Tibotec will fund certain R&D costs of ChemDiv. ChemDiv will be eligible for certain success milestones.

ChemDiv will conduct much of the research under this arrangement through its Moscow subsidiary, ChemDiv Research Institute (CDRI), anchored at the ChemRar High Tech Centre. The research will also be supported by ChemDiv's laboratories in San Diego.

Nikolay Savchuk, Chairman of ChemDiv Research Institute, comments: "We are focused on pioneering approaches to innovative R&D partnering at ChemDiv. Collaborative risk sharing under this strategic arrangement is aimed at fostering R&D productivity and broadening emerging market access. We are delighted to work with Janssen under a flexible entrepreneurial model more common to biotech ventures."

About ChemDiv Research Institute:
ChemDiv and its ChemDiv Research Institute (CDRI) subsidiary comprise a fully integrated discovery and development CRO based in San Diego and at the ChemRar High Tech Center in Moscow. CDRI collaborates with pharmaceutical and biotech partners by enabling them to accelerate R&D programs to higher value clinical inflection points. ChemDiv and its CDRI subsidiary offer integrated Discovery outSource™ solutions covering the complete range of disciplines, in multiple therapeutic areas (CNS, oncology, inflammation, metabolic, infectious diseases, and others), from discovery research and preclinical development, through accelerated Proof of Concept and to market registration.

Visit www.chemdiv.com for more information.


Contact for media:
Henrik Konarkowski
ChemDiv Research Institute
Email: Email Contact

Phone: +7-495-995-4944



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES